Acrizanib

Overview

Acrizanib (LHA510) is a VEGFR-2 inhibitor, with an IC 50 of 17.4 nM for BaF3-VEGFR-2.

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Gastric Cancer | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Pulmonary Disease | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Others | Products > Signaling Pathways > VEGFR

Product Information

• Catalog No.: HY-109020
• CAS No.: 1229453-99-9
• Molecular Formula: C20H18F3N7O2
• Molecular Weight: 445.40
• Purity: 99.84%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.08 mg/mL (4.67 mM); Clear solution
• Availability: In-stock

Source

Original product source